NCT05898256View on ClinicalTrials.gov

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2026

Conditions
Nasopharyngeal CarcinomaImmune Checkpoint Inhibitors
Interventions
DRUG

Cadonilimab

10mg/kg administered intravenously (IV)

DRUG

Gemcitabine

1 g/m2, administered as an IV infusion within 30 minutes

DRUG

Cisplatin

80 mg/m2, administered as an IV infusion over 4 hours

All Listed Sponsors
lead

Guangxi Medical University

OTHER

NCT05898256 - Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter